Two commercial tests related to genomic scars have been approved by the FDA and used to identify tumors with HRD: (1) the “myChoice HRD” kit by Myriad, which inquires the LOH, the TAI, and the LST throughout the genome [153], and (2) the “FoundationFocusTM CDx BRCA LOH”, which is conceived to identify the occurrence of variants in BRCA1/2 and the amount of the genome impacted by LOH in tumor-derived DNA of patients with OC [154]. Here, BRCA1 is linked to neoplasm.